
Publication|Articles|November 17, 2026
- November 2026
- Volume 92
- Issue 11
Recap: Phentolamine Ophthalmic Solution Approved for Presbyopia in Adults
A once-nightly drop already used to reverse pupil dilation gains a near-vision indication.
Advertisement
Advertisement
The FDA has approved phentolamine ophthalmic solution 0.75% (Ryzumvi; Viatris), an α-adrenergic antagonist eye drop, for the treatment of presbyopia in adults. The preservative-free drop is instilled once nightly. It offers a new pharmacologic option for the nearly 128 million individuals in the US with presbyopia, or about 90% of adults older than 45 years. Phentolamine ophthalmic solution was first approved for the reversal of pharmacologically induced mydriasis. Viatris says it is the only commercially available FDA-approved product for that use.1,2
Related to this article

Technology empowers patients and optimizes medication use.

Safe storage and responsible disposal help protect patients from accidental poisoning and drug misuse while keeping medications stable and effective.

Pharmacists can help identify uncontrolled risk factors, review medications, and reinforce when patients should seek emergency care.

The anti-CD20 antibody is the first drug approved specifically for the disease, based on phase 3 MAJESTY data showing higher remission vs tacrolimus.
Advertisement
Advertisement




